HALO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $15,820,998.73

Halozyme Therapeutics Insider Trading History Chart

Halozyme Therapeutics Share Price & Price History

^$62.95

▼ -1.71 (-2.64%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Halozyme Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2025	Bernadette Connaughton	Director	Sell	829	$71.60	$59,356.40	42,123
12/1/2025	Helen Torley	CEO	Sell	16,569	$68.92	$1,141,935.48	708,719
11/11/2025	Helen Torley	CEO	Sell	20,000	$69.13	$1,382,600.00	733,719
11/10/2025	Bernadette Connaughton	Director	Sell	2,000	$68.48	$136,960.00	42,952
10/3/2025	Helen Torley	CEO	Sell	20,000	$69.03	$1,380,600.00	733,719
10/1/2025	Bernadette Connaughton	Director	Sell	2,000	$75.24	$150,480.00	44,952
10/1/2025	Helen Torley	CEO	Sell	20,000	$75.35	$1,507,000.00	733,719
9/22/2025	Nicole Labrosse	CFO	Sell	2,227	$77.95	$173,594.65	22,079
9/10/2025	Nicole Labrosse	CFO	Sell	20,000	$75.71	$1,514,200.00	24,306
9/3/2025	Helen Torley	CEO	Sell	20,000	$74.44	$1,488,800.00	733,719
9/2/2025	Bernadette Connaughton	Director	Sell	4,000	$73.68	$294,720.00	46,952
8/12/2025	Helen Torley	CEO	Sell	20,000	$63.51	$1,270,200.00	733,719
7/9/2025	Helen Torley	CEO	Sell	20,000	$56.43	$1,128,600.00	733,719
6/24/2025	Helen Torley	CEO	Sell	20,000	$53.73	$1,074,600.00	733,719
6/20/2025	Helen Torley	CEO	Sell	20,000	$52.96	$1,059,200.00	733,719
4/28/2025	Jeffrey William Henderson	Director	Sell	4,497	$60.37	$271,483.89	28,611
4/1/2025	Jeffrey William Henderson	Director	Sell	503	$64.05	$32,217.15	33,108
3/3/2025	Jeffrey William Henderson	Director	Sell	5,000	$58.69	$293,450.00	33,611
2/27/2025	Michael J. LaBarre	SVP	Sell	1,697	$58.28	$98,901.16	173,756
2/25/2025	Michael J. LaBarre	SVP	Sell	10,000	$58.05	$580,500.00	185,453
2/3/2025	Jeffrey William Henderson	Director	Sell	5,000	$56.30	$281,500.00	38,611
1/6/2025	Jeffrey William Henderson	Director	Sell	10,000	$50.01	$500,100.00	43,611
10/16/2024	Michael J. LaBarre	SVP	Sell	10,000	$53.26	$532,600.00	173,756
10/9/2024	Helen Torley	CEO	Sell	10,000	$52.58	$525,800.00	676,744
9/25/2024	Helen Torley	CEO	Sell	10,000	$56.34	$563,400.00	676,744
9/18/2024	Michael J. LaBarre	SVP	Sell	10,000	$62.03	$620,300.00	173,756
9/12/2024	Helen Torley	CEO	Sell	10,000	$59.20	$592,000.00	676,744
9/10/2024	Helen Torley	CEO	Sell	10,000	$59.09	$590,900.00	676,744
8/21/2024	Michael J. LaBarre	SVP	Sell	10,000	$61.75	$617,500.00	168,176
8/14/2024	Matthew L. Posard	Director	Sell	9,881	$57.70	$570,133.70	69,874
8/12/2024	Matthew L. Posard	Director	Sell	10,000	$55.72	$557,200.00	89,755
7/24/2024	Michael J. LaBarre	SVP	Sell	10,000	$55.12	$551,200.00	168,176
7/22/2024	Nicole Labrosse	CFO	Sell	5,000	$53.93	$269,650.00	15,480
6/27/2024	Nicole Labrosse	CFO	Sell	10,000	$51.93	$519,300.00	15,480
6/11/2024	Matthew L. Posard	Director	Sell	10,000	$50.01	$500,100.00	109,755
5/22/2024	Michael J. LaBarre	SVP	Sell	10,000	$45.38	$453,800.00	168,176
4/17/2024	Michael J. LaBarre	SVP	Sell	10,000	$38.49	$384,900.00	168,176
3/12/2024	Michael J. LaBarre	SVP	Sell	10,000	$41.64	$416,400.00	156,558
2/28/2024	Michael J. LaBarre	SVP	Sell	10,000	$39.55	$395,500.00	156,558
12/12/2023	Michael J. LaBarre	SVP	Sell	10,000	$39.63	$396,300.00	151,911
10/17/2023	Michael J. LaBarre	SVP	Sell	10,000	$36.52	$365,200.00	151,911
9/19/2023	Michael J. LaBarre	SVP	Sell	10,000	$39.10	$391,000.00	151,911
8/31/2023	Helen Torley	CEO	Sell	10,000	$42.82	$428,200.00	623,666
8/29/2023	Helen Torley	CEO	Sell	10,000	$42.40	$424,000.00	623,666
8/22/2023	Michael J. LaBarre	SVP	Sell	10,000	$42.41	$424,100.00	151,911
8/22/2023	Michael J. LaBarre	SVP	Sell	10,000	$42.41	$424,100.00	151,911
8/17/2023	Helen Torley	CEO	Sell	10,000	$43.18	$431,800.00	623,666
8/14/2023	James M. Daly	Director	Sell	10,000	$43.74	$437,400.00	20,503
8/11/2023	James M. Daly	Director	Sell	10,000	$43.71	$437,100.00	30,503
7/26/2023	Helen Torley	CEO	Sell	10,000	$42.69	$426,900.00	623,666
7/18/2023	Michael J. LaBarre	SVP	Sell	10,000	$40.43	$404,300.00	141,911
6/21/2023	Michael J. LaBarre	SVP	Sell	10,000	$36.00	$360,000.00	141,911
4/18/2023	Michael J. LaBarre	SVP	Sell	10,000	$36.00	$360,000.00	141,911
3/9/2023	Helen Torley	CEO	Sell	10,000	$42.73	$427,300.00	623,666
3/7/2023	Helen Torley	CEO	Sell	10,000	$45.47	$454,700.00	623,666
3/1/2023	Jeffrey William Henderson	Director	Sell	10,000	$47.71	$477,100.00	39,045
2/27/2023	Michael J. LaBarre	SVP	Sell	10,000	$49.55	$495,500.00	138,927
2/16/2023	Helen Torley	CEO	Sell	11,061	$49.26	$544,864.86	633,666
2/16/2023	Nicole Labrosse	CFO	Sell	2,525	$49.26	$124,381.50	9,066
2/15/2023	Michael J. LaBarre	SVP	Sell	10,000	$48.39	$483,900.00	143,477
2/8/2023	Helen Torley	CEO	Sell	10,000	$51.36	$513,600.00	587,177
1/19/2023	Helen Torley	CEO	Sell	10,000	$52.41	$524,100.00	587,177
1/17/2023	Michael J. LaBarre	SVP	Sell	10,000	$50.46	$504,600.00	143,137
12/15/2022	Helen Torley	CEO	Sell	10,000	$57.37	$573,700.00	587,177
12/13/2022	Michael J. LaBarre	SVP	Sell	10,000	$58.67	$586,700.00	153,137
12/5/2022	Matthew L. Posard	Director	Sell	10,000	$55.74	$557,400.00	115,189
12/2/2022	Matthew L. Posard	Director	Sell	10,000	$58.80	$588,000.00	125,189

SEC Filings (Institutional Ownership Changes) for Halozyme Therapeutics (NASDAQ:HALO)

97.79% of Halozyme Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Halozyme Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/2/2025	Allworth Financial LP	39,736	$2.91M	0.0%	+322.5%	0.034%
12/2/2025	IFP Advisors Inc	5,206	$0.38M	0.0%	+17.8%	0.004%
12/2/2025	Swiss Life Asset Management Ltd	5,815	$0.43M	0.0%	N/A	0.005%
11/24/2025	CIBC Private Wealth Group LLC	2,891	$0.21M	0.0%	+12.8%	0.002%
11/19/2025	Captrust Financial Advisors	48,188	$3.53M	0.0%	-1.8%	0.041%
11/19/2025	Coldstream Capital Management Inc.	8,914	$0.65M	0.0%	+1.9%	0.008%
11/19/2025	Danske Bank A S	62,771	$4.60M	0.0%	N/A	0.053%
11/19/2025	Caitong International Asset Management Co. Ltd	2,044	$0.15M	0.1%	+1,677.4%	0.002%
11/18/2025	Advisory Services Network LLC	13,094	$0.96M	0.0%	+12.4%	0.011%
11/18/2025	Cim Investment Management Inc.	8,629	$0.63M	0.2%	-51.9%	0.007%
11/18/2025	Livforsakringsbolaget Skandia Omsesidigt	104,900	$7.69M	0.3%	+2.8%	0.089%
11/17/2025	Hancock Whitney Corp	246,221	$18.06M	0.3%	+4.4%	0.209%
11/17/2025	Abel Hall LLC	3,087	$0.23M	0.1%	N/A	0.003%
11/17/2025	Jacobs Levy Equity Management Inc.	898,192	$65.87M	0.3%	-10.4%	0.764%
11/17/2025	Oberweis Asset Management Inc.	117,580	$8.62M	0.3%	-35.5%	0.100%
11/17/2025	NewEdge Advisors LLC	6,933	$0.51M	0.0%	+5,582.8%	0.006%
11/17/2025	Vivaldi Capital Management LP	33,141	$2.43M	0.3%	-5.3%	0.028%
11/17/2025	CANADA LIFE ASSURANCE Co	93,274	$6.83M	0.0%	-22.0%	0.079%
11/17/2025	Dark Forest Capital Management LP	38,217	$2.80M	0.1%	N/A	0.032%
11/17/2025	XTX Topco Ltd	21,340	$1.57M	0.1%	-28.6%	0.018%
11/17/2025	United Capital Financial Advisors LLC	14,414	$1.06M	0.0%	N/A	0.012%
11/17/2025	Voleon Capital Management LP	6,780	$0.50M	0.0%	N/A	0.006%
11/17/2025	Voloridge Investment Management LLC	1,057,902	$77.59M	0.3%	N/A	0.900%
11/17/2025	Wexford Capital LP	954	$70K	0.0%	N/A	0.001%
11/17/2025	Verition Fund Management LLC	68,167	$5M	0.0%	+103.3%	0.058%
11/17/2025	Verity Asset Management Inc.	47,612	$3.49M	1.1%	+7.2%	0.040%
11/17/2025	Scientech Research LLC	11,830	$0.87M	0.3%	-73.0%	0.010%
11/17/2025	Polymer Capital Management US LLC	10,881	$0.80M	0.1%	N/A	0.009%
11/17/2025	Qube Research & Technologies Ltd	601,276	$44.10M	0.0%	-39.0%	0.511%
11/17/2025	Public Employees Retirement System of Ohio	38,894	$2.85M	0.0%	+0.7%	0.033%
11/17/2025	Northern Trust Corp	1,167,141	$85.60M	0.0%	+9.4%	0.992%
11/17/2025	Mercer Global Advisors Inc. ADV	11,762	$0.86M	0.0%	N/A	0.010%
11/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	13,537	$0.99M	0.0%	-4.7%	0.012%
11/17/2025	Laird Norton Wetherby Wealth Management LLC	7,912	$0.58M	0.0%	-16.0%	0.007%
11/17/2025	Larson Financial Group LLC	354	$26K	0.0%	+3,118.2%	0.000%
11/17/2025	Integrated Wealth Concepts LLC	3,335	$0.25M	0.0%	N/A	0.003%
11/17/2025	Holocene Advisors LP	14,409	$1.06M	0.0%	N/A	0.012%
11/17/2025	Gotham Asset Management LLC	252,934	$18.55M	0.1%	+271.7%	0.215%
11/17/2025	Fred Alger Management LLC	7,906	$0.58M	0.0%	-73.2%	0.007%
11/17/2025	Focus Partners Wealth	123,093	$9.01M	0.0%	-7.2%	0.105%
11/17/2025	Brevan Howard Capital Management LP	64,217	$4.71M	0.0%	-60.1%	0.055%
11/17/2025	Clark Capital Management Group Inc.	202,965	$14.89M	0.1%	+14.4%	0.173%
11/17/2025	Bridgefront Capital LLC	6,815	$0.50M	0.1%	+4.5%	0.006%
11/17/2025	California Public Employees Retirement System	249,526	$18.30M	0.0%	+5.9%	0.212%
11/17/2025	Cantor Fitzgerald L. P.	12,200	$0.90M	0.0%	N/A	0.010%
11/17/2025	Bank of Nova Scotia	80,700	$5.92M	0.0%	N/A	0.069%
11/17/2025	Aquatic Capital Management LLC	89,651	$6.58M	0.1%	N/A	0.076%
11/17/2025	ArrowMark Colorado Holdings LLC	924,875	$67.83M	1.3%	+6.7%	0.786%
11/17/2025	Algert Global LLC	59,310	$4.35M	0.1%	+21.9%	0.050%
11/17/2025	Alliancebernstein L.P.	1,907,355	$139.89M	0.0%	-22.3%	1.622%
11/14/2025	Schonfeld Strategic Advisors LLC	61,683	$4.52M	0.0%	+1.4%	0.052%
11/14/2025	Creative Planning	55,294	$4.06M	0.0%	+9.2%	0.047%
11/14/2025	AQR Capital Management LLC	968,511	$71.03M	0.0%	+155.7%	0.824%
11/14/2025	Zacks Investment Management	26,121	$1.92M	0.0%	N/A	0.022%
11/14/2025	Credit Agricole S A	38,855	$2.85M	0.0%	N/A	0.033%
11/14/2025	Raymond James Financial Inc.	281,447	$20.64M	0.0%	+11.1%	0.239%
11/14/2025	Virtu Financial LLC	11,238	$0.82M	0.0%	-49.2%	0.010%
11/14/2025	Amundi	8,978	$0.60M	0.0%	-99.9%	0.008%
11/14/2025	Panoramic Capital LLC	89,426	$6.56M	2.9%	-0.6%	0.076%
11/14/2025	Caisse de depot et placement du Quebec	776,635	$56.96M	0.1%	-42.1%	0.660%
11/14/2025	Hotchkis & Wiley Capital Management LLC	134,630	$9.87M	0.0%	N/A	0.114%
11/14/2025	California State Teachers Retirement System	116,670	$8.56M	0.0%	-3.8%	0.099%
11/14/2025	One Capital Management LLC	33,558	$2.46M	0.1%	+52.5%	0.029%
11/14/2025	Horizon Investments LLC	35,461	$2.60M	0.0%	+23.3%	0.030%
11/14/2025	Fiduciary Trust Co	5,732	$0.42M	0.0%	-15.1%	0.005%
11/14/2025	Brooklyn Investment Group	12,412	$0.91M	0.1%	+378.3%	0.011%
11/14/2025	UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC	326,967	$23.98M	0.0%	-53.0%	0.278%
11/14/2025	Two Sigma Investments LP	1,315,924	$96.51M	0.1%	-86.1%	1.119%
11/14/2025	Squarepoint Ops LLC	357,948	$26.25M	0.0%	+46.1%	0.304%
11/14/2025	2Xideas AG	158,824	$11.65M	2.5%	-13.9%	0.135%
11/14/2025	South Street Advisors LLC	247,852	$18.18M	2.4%	+2.7%	0.211%
11/14/2025	Harvest Fund Management Co. Ltd	4,894	$0.36M	0.0%	+97,780.0%	0.004%
11/14/2025	Prudential PLC	39,173	$2.87M	0.0%	-8.5%	0.033%
11/14/2025	Newbridge Financial Services Group Inc.	467	$34K	0.0%	-24.8%	0.000%
11/14/2025	FORA Capital LLC	16,832	$1.23M	0.2%	N/A	0.014%
11/14/2025	Glenmede Investment Management LP	175,687	$12.89M	0.1%	+3.8%	0.149%
11/13/2025	Jump Financial LLC	41,779	$3.06M	0.0%	+250.8%	0.036%
11/13/2025	Epoch Investment Partners Inc.	596,606	$43.76M	0.2%	-5.6%	0.507%
11/13/2025	Boston Partners	444,803	$32.08M	0.0%	-1.0%	0.378%
11/13/2025	Marshall Wace LLP	393,755	$28.88M	0.0%	+1.2%	0.335%
11/13/2025	Entropy Technologies LP	35,638	$2.61M	0.2%	N/A	0.030%
11/13/2025	Landscape Capital Management L.L.C.	18,431	$1.35M	0.1%	N/A	0.016%
11/13/2025	Kennedy Capital Management LLC	383,557	$28.13M	0.6%	-7.6%	0.326%
11/13/2025	Quantitative Investment Management LLC	3,773	$0.28M	0.0%	N/A	0.003%
11/13/2025	Arrowstreet Capital Limited Partnership	3,290,665	$241.34M	0.2%	+29.5%	2.798%
11/13/2025	Employees Retirement System of Texas	1,088	$80K	0.0%	+64.6%	0.001%
11/13/2025	Capital Fund Management S.A.	212,741	$15.60M	0.0%	+97.1%	0.181%
11/13/2025	Mackenzie Financial Corp	35,331	$2.59M	0.0%	-70.2%	0.030%
11/13/2025	Magnetar Financial LLC	12,216	$0.90M	0.0%	N/A	0.010%
11/13/2025	Quadrant Capital Group LLC	8,505	$0.62M	0.0%	+3.6%	0.007%
11/13/2025	Van ECK Associates Corp	8,298	$0.61M	0.0%	-36.8%	0.007%
11/13/2025	Claret Asset Management Corp	4,326	$0.32M	0.0%	N/A	0.004%
11/13/2025	Legal & General Group Plc	334,419	$24.53M	0.0%	-0.9%	0.284%
11/13/2025	Vestcor Inc	42,811	$3.14M	0.1%	-4.0%	0.036%
11/13/2025	Fieldview Capital Management LLC	10,705	$0.79M	0.1%	N/A	0.009%
11/13/2025	Swiss National Bank	238,900	$17.52M	0.0%	+1.2%	0.203%
11/13/2025	WINTON GROUP Ltd	3,500	$0.26M	0.0%	N/A	0.003%
11/13/2025	DLD Asset Management LP	30,000,000	$2.20B	11.8%	+20.0%	25.511%
11/13/2025	Schroder Investment Management Group	135,565	$9.94M	0.0%	-45.1%	0.115%
11/13/2025	Inceptionr LLC	8,200	$0.60M	0.1%	-39.7%	0.007%

Data available starting January 2016

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Today's Range

Now: $62.95

$61.70

$66.00

50 Day Range

MA: $68.39

$62.95

$74.94

52 Week Range

Now: $62.95

$46.26

$79.50

Volume

4,212,997 shs

Average Volume

2,568,124 shs

Market Capitalization

$7.40 billion

P/E Ratio

13.25

Dividend Yield

N/A

Beta

0.95

Who are the company insiders with the largest holdings of Halozyme Therapeutics?: Halozyme Therapeutics' top insider shareholders include:
Helen Torley (CEO)
Michael J Labarre (SVP)
Matthew L Posard (Director)
Bernadette Connaughton (Director)
Jeffrey William Henderson (Director)
Nicole Labrosse (CFO)
Learn More about top insider investors at Halozyme Therapeutics.
Who are the major institutional investors of Halozyme Therapeutics?: Halozyme Therapeutics' top institutional investors include:
DLD Asset Management LP — 25.51%
Vanguard Group Inc. — 9.94%
Arrowstreet Capital Limited Partnership — 2.80%
Snyder Capital Management L P — 2.32%
Dimensional Fund Advisors LP — 1.77%
Alliancebernstein L.P. — 1.62%
Learn More about top institutional investors of Halozyme Therapeutics stock.
Which major investors are selling Halozyme Therapeutics stock?: Within the last quarter, HALO stock was sold by these institutional investors:
Two Sigma Investments LP
Amundi
New York State Common Retirement Fund
Artisan Partners Limited Partnership
Snyder Capital Management L P
Vanguard Group Inc.
Caisse de depot et placement du Quebec
Alliancebernstein L.P.
In the last year, company insiders that have sold Halozyme Therapeutics company stock include:
Helen Torley (CEO)
Michael J Labarre (SVP)
Matthew L Posard (Director)
Bernadette Connaughton (Director)
Jeffrey William Henderson (Director)
Learn More investors selling Halozyme Therapeutics stock.
Which major investors are buying Halozyme Therapeutics stock?: Within the last quarter, HALO stock was acquired by institutional investors including:
DLD Asset Management LP
Federated Hermes Inc.
Voloridge Investment Management LLC
Arrowstreet Capital Limited Partnership
AQR Capital Management LLC
Renaissance Group LLC
Pacer Advisors Inc.
Gotham Asset Management LLC